Literature DB >> 19037234

Frequencies of NRAS and BRAF mutations increase from the radial to the vertical growth phase in cutaneous melanoma.

Victoria R Greene1, Marcella M Johnson, Elizabeth A Grimm, Julie A Ellerhorst.   

Abstract

A lack of consensus exists with regards to the relative rates of NRAS and BRAF mutations in the radial (RGP) and vertical (VGP) growth phases of individual melanoma tumors. This study was conducted to test the hypothesis that mutations are acquired with progression from RGP to VGP. Using laser capture microdissection, pure tumor DNA was obtained from 15 in situ melanomas, and from the RGP and VGP of 29 invasive tumors. NRAS exon 2 and BRAF exon 15 DNA were amplified by PCR and sequenced. Mutations were present in 6 of 15 in situ melanomas (40%). Of 29 invasive tumors, 16 exhibited RGP mutations (55.2%); 22 showed VGP mutations (75.9%). Paired RGP/VGP mutation analysis revealed a trend toward discordance in the distribution of mutations, favoring VGP localization (P=0.07). Of 15 samples, 12 with mutations in both phases had an increased proportion of mutated DNA in the VGP, measured on DNA chromatograms (P=0.08). Limitations of this study include a relatively small sample cohort selected for technical reasons from a larger population, presenting the risk of selection bias. These concerns notwithstanding our findings support the hypothesis that NRAS and BRAF mutations increase with tumor progression from superficial to invasive disease. JID JOURNAL CLUB ARTICLE: For questions, answers, and open discussion about this article, please go to http://network.nature.com/group/jidclub.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19037234      PMCID: PMC2741006          DOI: 10.1038/jid.2008.374

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  24 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

2.  NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.

Authors:  Esther Edlundh-Rose; Suzanne Egyházi; Katarina Omholt; Eva Månsson-Brahme; Anton Platz; Johan Hansson; Joakim Lundeberg
Journal:  Melanoma Res       Date:  2006-12       Impact factor: 3.599

3.  Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.

Authors:  Vikas K Goel; Alexander J F Lazar; Carla L Warneke; Mark S Redston; Frank G Haluska
Journal:  J Invest Dermatol       Date:  2006-01       Impact factor: 8.551

4.  Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma.

Authors:  A Demunter; M Stas; H Degreef; C De Wolf-Peeters; J J van den Oord
Journal:  J Invest Dermatol       Date:  2001-12       Impact factor: 8.551

5.  Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression.

Authors:  Katarina Omholt; Sofia Karsberg; Anton Platz; Lena Kanter; Ulrik Ringborg; Johan Hansson
Journal:  Clin Cancer Res       Date:  2002-11       Impact factor: 12.531

6.  High frequency of BRAF mutations in nevi.

Authors:  Pamela M Pollock; Ursula L Harper; Katherine S Hansen; Laura M Yudt; Mitchell Stark; Christiane M Robbins; Tracy Y Moses; Galen Hostetter; Urs Wagner; John Kakareka; Ghadi Salem; Tom Pohida; Peter Heenan; Paul Duray; Olli Kallioniemi; Nicholas K Hayward; Jeffrey M Trent; Paul S Meltzer
Journal:  Nat Genet       Date:  2002-11-25       Impact factor: 38.330

7.  Mutations of the BRAF gene in benign and malignant melanocytic lesions.

Authors:  Amir S Yazdi; Gabriele Palmedo; Michael J Flaig; Ursula Puchta; Andrea Reckwerth; Arno Rütten; Thomas Mentzel; Heino Hügel; Markus Hantschke; Monika-Hildegard Schmid-Wendtner; Heinz Kutzner; Christian A Sander
Journal:  J Invest Dermatol       Date:  2003-11       Impact factor: 8.551

Review 8.  Laser-capture microdissection: opening the microscopic frontier to molecular analysis.

Authors:  N L Simone; R F Bonner; J W Gillespie; M R Emmert-Buck; L A Liotta
Journal:  Trends Genet       Date:  1998-07       Impact factor: 11.639

9.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

10.  Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis.

Authors:  Roland Houben; Jürgen C Becker; Andreas Kappel; Patrick Terheyden; Eva-B Bröcker; Rudolf Goetz; Ulf R Rapp
Journal:  J Carcinog       Date:  2004-03-26
View more
  21 in total

1.  Trends in the diagnosis and clinical features of melanoma in situ (MIS) in US men and women: A prospective, observational study.

Authors:  Erin X Wei; Abrar A Qureshi; Jiali Han; Tricia Y Li; Eunyoung Cho; Jennifer Y Lin; Wen-Qing Li
Journal:  J Am Acad Dermatol       Date:  2016-07-16       Impact factor: 11.527

2.  Clinical correlates of NRAS and BRAF mutations in primary human melanoma.

Authors:  Julie A Ellerhorst; Victoria R Greene; Suhendan Ekmekcioglu; Carla L Warneke; Marcella M Johnson; Carolyn P Cooke; Li-E Wang; Victor G Prieto; Jeffrey E Gershenwald; Qingyi Wei; Elizabeth A Grimm
Journal:  Clin Cancer Res       Date:  2010-10-25       Impact factor: 12.531

3.  Risk factors for malignant melanoma in white and non-white/non-African American populations: the multiethnic cohort.

Authors:  Sungshim Lani Park; Loïc Le Marchand; Lynne R Wilkens; Laurence N Kolonel; Brian E Henderson; Zuo-Feng Zhang; Veronica Wendy Setiawan
Journal:  Cancer Prev Res (Phila)       Date:  2012-01-13

Review 4.  Novel anti-cancer compounds for developing combinatorial therapies to target anoikis-resistant tumors.

Authors:  Lokesh Nagaprashantha; Neha Vartak; Sangeeta Awasthi; Sanjay Awasthi; Sharad S Singhal
Journal:  Pharm Res       Date:  2011-12-28       Impact factor: 4.200

5.  Tumor-promoting role of signal transducer and activator of transcription (Stat)1 in late-stage melanoma growth.

Authors:  Julia Schultz; Dirk Koczan; Ulf Schmitz; Saleh M Ibrahim; Dominik Pilch; Jenny Landsberg; Manfred Kunz
Journal:  Clin Exp Metastasis       Date:  2010-02-24       Impact factor: 5.150

Review 6.  Phytochemicals for the Management of Melanoma.

Authors:  Harish Chandra Pal; Katherine Marchiony Hunt; Ariana Diamond; Craig A Elmets; Farrukh Afaq
Journal:  Mini Rev Med Chem       Date:  2016       Impact factor: 3.862

Review 7.  Targeted therapy for melanoma: a primer.

Authors:  Michael A Davies; Jeffrey E Gershenwald
Journal:  Surg Oncol Clin N Am       Date:  2011-01       Impact factor: 3.495

8.  PD-L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation.

Authors:  Nemanja Rodić; Robert A Anders; James R Eshleman; Ming-Tseh Lin; Haiying Xu; Jung H Kim; Katie Beierl; Shuming Chen; Brandon S Luber; Hao Wang; Suzanne L Topalian; Drew M Pardoll; Janis M Taube
Journal:  Cancer Immunol Res       Date:  2014-11-04       Impact factor: 11.151

9.  Genetics of uveal melanoma and cutaneous melanoma: two of a kind?

Authors:  Thomas van den Bosch; Emine Kilic; Dion Paridaens; Annelies de Klein
Journal:  Dermatol Res Pract       Date:  2010-06-06

Review 10.  Main roads to melanoma.

Authors:  Giuseppe Palmieri; Mariaelena Capone; Maria Libera Ascierto; Giusy Gentilcore; David F Stroncek; Milena Casula; Maria Cristina Sini; Marco Palla; Nicola Mozzillo; Paolo A Ascierto
Journal:  J Transl Med       Date:  2009-10-14       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.